Skip to main content
logo
KalVista Pharmaceuticals, Inc. (KALV)
Jun 11, 2026 - KALV was delisted (reason: acquired by Chiesi Group)
27.00
+0.01 (0.04%)
Inactive · Last trade price on Jun 10, 2026

KalVista Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2025FY 2024FY FY 2023
Period Ending
Jun '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
Market Capitalization
1,438816685479500291
Market Cap Growth
153.62%19.24%42.97%-4.30%71.67%-6.71%
Enterprise Value
1,437790538411432128
Last Close Price
27.0016.1513.7711.3511.868.53

Price Ratios

Fiscal Year
CurrentFY 2025FY 2025FY 2024FY FY 2023
Period Ending
Jun '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
PS Ratio
12.5611.09----
PB Ratio
--301.117.182.32-1.81
P/TBV Ratio
--7.182.32-1.81

EV Ratios

Fiscal Year
CurrentFY 2025FY 2025FY 2024FY FY 2023
Period Ending
Jun '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
EV/Sales Ratio
12.5510.73----

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2025FY 2024FY FY 2023
Period Ending
Jun '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
Debt / Equity Ratio
-14.47-104.831.180.04-0.05
Net Debt / Equity Ratio
0.045.90-1.14-0.98--0.88
Net Debt / EBITDA Ratio
0.010.100.581.45-1.28
Net Debt / FCF Ratio
0.010.130.712.28-1.85
Quick Ratio
4.975.435.229.70-11.18
Current Ratio
5.175.585.359.90-11.46
Return on Equity (ROE)
---121.50%-68.90%--53.69%
Return on Assets (ROA)
---48.34%-41.94%--35.80%
Return on Capital Employed (ROCE)
-52.20%-59.80%-91.40%-66.10%--65.90%

Yields

Fiscal Year
CurrentFY 2025FY 2025FY 2024FY FY 2023
Period Ending
Jun '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
Earnings Yield
-9.46%-20.13%-26.80%-26.45%--31.88%
FCF Yield
-6.38%-15.31%-22.40%-18.64%--26.23%
Buyback Yield / Dilution
-9.26%-8.49%-34.98%---13.96%
SEC Filings: 10-K · 10-Q